VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 410 filers reported holding VALEANT PHARMACEUTICALS INTL in Q4 2013. The put-call ratio across all filers is 0.62 and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $3,357,000 | +150.1% | 231,179 | +322.8% | 0.08% | +159.4% |
| Q3 2016 | $1,342,000 | -31.7% | 54,679 | -44.0% | 0.03% | -22.0% |
| Q2 2016 | $1,966,000 | +142.4% | 97,627 | +216.7% | 0.04% | +78.3% |
| Q1 2016 | $811,000 | -24.8% | 30,824 | +190.3% | 0.02% | +27.8% |
| Q4 2015 | $1,079,000 | -83.6% | 10,618 | -71.2% | 0.02% | -83.3% |
| Q3 2015 | $6,580,000 | +44.2% | 36,890 | +79.6% | 0.11% | +31.7% |
| Q2 2015 | $4,563,000 | +552.8% | 20,541 | +483.6% | 0.08% | +485.7% |
| Q1 2015 | $699,000 | +183.0% | 3,520 | +105.1% | 0.01% | +250.0% |
| Q4 2014 | $247,000 | -14.8% | 1,716 | -22.5% | 0.00% | -33.3% |
| Q3 2014 | $290,000 | -93.6% | 2,214 | -93.6% | 0.01% | -89.5% |
| Q1 2014 | $4,562,000 | +6.9% | 34,599 | -4.8% | 0.06% | +21.3% |
| Q4 2013 | $4,267,000 | -93.4% | 36,346 | -94.2% | 0.05% | -94.3% |
| Q3 2013 | $65,082,000 | – | 623,817 | – | 0.83% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Brave Warrior Advisors | 6,050,442 | $763,082,000 | 30.78% |
| LeVasseur Capital Partners LLC | 190,404 | $24,014,000 | 29.50% |
| FARLEY CAPITAL L.P. | 333,081 | $42,008,000 | 27.09% |
| Ruane, Cunniff & Goldfarb | 34,298,384 | $4,325,712,000 | 23.07% |
| ValueAct Holdings | 18,923,877 | $2,386,679,000 | 17.64% |
| Tesuji Partners | 1,368,040 | $172,537,000 | 17.22% |
| Brahman Capital Corp. | 3,902,877 | $492,231,000 | 13.63% |
| Arrow Capital Management, LLC | 197,500 | $24,909,000 | 13.60% |
| Hound Partners | 2,851,175 | $359,590,000 | 13.45% |
| Ratan Capital Management LP | 731,960 | $92,315,000 | 13.09% |